Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $26.39 +0.50%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
Revenue Growth %: -23.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
Revenue Growth %: -23.7%
Join SI Premium – FREE
Pfizer Inc. (NYSE: PFE) named Olivier Brandicourt as President and General Manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012. He will succeed David Simmons, who is leaving Pfizer to become the Chairman and CEO of Pharmaceutical Product Development Inc. (PPD), a privately held global contract research organization.
Brandicourt has held senior positions at Pfizer across a range of disciplines, including medical and marketing, as well as country and regional management roles in Latin America, Europe, Canada, the United Kingdom and the United States. Most recently, he served as President and General Manager of the Primary Care Business Unit and is a member of the Pfizer Executive Leadership Team. He is an Honorary Fellow of the Royal College of Physicians in London and a trustee of the Children’s Aid Society of New York.
Brandicourt has held senior positions at Pfizer across a range of disciplines, including medical and marketing, as well as country and regional management roles in Latin America, Europe, Canada, the United Kingdom and the United States. Most recently, he served as President and General Manager of the Primary Care Business Unit and is a member of the Pfizer Executive Leadership Team. He is an Honorary Fellow of the Royal College of Physicians in London and a trustee of the Children’s Aid Society of New York.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- Pfizer (PFE) Announces EC Approves EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
